Breast Cancer

Investigators call for further public awareness of other breast cancer risk factors, besides dense breasts, which could help identify more women who are at high risk.

Race, ethnicity, years after diagnosis and mental and physical stress are among factors associated with unmet supportive care needs and a higher risk of hospitalization among patients with cancer.

Increases in biological aging based on epigenetic measures could be used to inform the future of survivorship care among patients with breast cancer.

The single institution study compared fixed dose capecitabine to standard dose capecitabine to compare efficacy and tolerability in metastatic breast cancer.

The benefit of ribociclib was seen as consistent against all of the stratification factors in the phase III study.

Both immunotherapies and targeted therapies are showing significant promise in these areas, offering patients new treatment options.

Andrea Iannucci, PharmD, BCOP, assistant chief pharmacy officer at UC Davis Health, discussed challenges and opportunities when implementing new treatments for breast cancer.

Depression can affect the trajectory of treatment and associated outcomes.

Capivasertib combined with fulvestrant doubled progression-free survival in patients with recurrent or progressed advanced stage HR-positive HER2-negative breast cancer compared to placebo.

There are 8 million cancer survivors who may have limitations in their daily functional ability.

The meeting aims to bring together pharmacists to discuss solutions for responding to the rapidly evolving evidence and needs for effective implementation.

When physicians followed up, rates of screening improved for breast and cervical cancer by 50% and 250%, respectively, among eligible cancer survivors.

FR alpha expression is limited on normal cells, but upregulated on cancers such as ovarian, endometrial, and triple-negative breast cancers.

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.

Program Chair Ryan Haumschild, PharmD, MS, MBA, discussed what attendees can look forward to at the inaugural Oncology Pharmacists Connect meeting.

Specialty pharmacists—those caring for patients with serious, sometimes life-threatening conditions such as cancer or rheumatologic disease—are not immune from the ongoing labor crisis.

The imaging agent and visualization system will be an adjunct to standard of care to reduce residual cancer in the lumpectomy cavity during initial surgery.

US Preventive Services Task Force also called for more research into how to address screening and treatment disparities faced by racial and ethnic minorities.

Alpelisib plus the antioxidant N-acetylcysteine sensitizes NF1 knockout cells to PI3Kα inhibition and reverts their glycolytic phenotype in patients with advanced forms of breast cancer.

Study examines association between breast cancer survival and neighborhood-level measures such as socioeconomic status.

The system is considered effective at identifying residual breast cancer following surgical resection.

Infusion reactions in the switching group did not occur with switching, but rather only with reference trastuzumab administration.

Study results show significant differences in pCR rates, but the differences were not subtype-specific.

Oncology pharmacist discusses recent clinical trial data and what it could mean for patient outcomes.

Certain populations have been found to have differing prognoses, such as African American patients, who have an earlier onset of disease with a higher likelihood of an aggressive tumor type and shorter survival.

The implementation of genetic testing for patients prescribed medications associated with progressive multifocal leukoencephalopathy is likely to improve safety outcomes.

Ribociclib plus endocrine therapy demonstrates a reduction in the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

Drugs such as pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan all have growing bodies of evidence illustrating which patients with cancer are most likely to benefit and in which settings.

3D biofabrication models reflect increasing global awareness of the ethics of preclinical studies and an increased need for determining therapeutic efficacy differences.

Therapy effectively treats cells harboring HR deficiencies, including those of specific types of ovarian, breast cancers.